Erectile Dysfunction: Anatomical Parameters, Etiology, Diagnosis, and Therapy

Hafez, E. S. E.; Hafez, S D

doi:10.1080/1485010490475147

Cited by 43 publications

(23 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many drugs can induce this adverse effect (e.g. antiadrogenic, anticholinergic, antidepressants, antihypertensive, major tranquilizers, and anxiolytics drugs) [109], but the situation with lipid lowering drugs is less clear. Statins in particular have become widely used but are not generally accepted as a cause of ED.…”

Section: Lipids and The Treatment Of Edmentioning

confidence: 99%

Dyslipidemia as a Risk Factor for Erectile Dysfunction

Vrentzos¹,

Paraskevas²,

Mikhailidis

2007

CMC

View full text Add to dashboard Cite

Erectile dysfunction (ED) is a common condition with a significant effect on quality of life. The prevalence of ED increases with age and other risk factors (hypertension, diabetes, smoking, coronary heart disease, dyslipidemia and depression). Nitric oxide (NO) activity is adversely affected, in penile and vascular tissue, by these risk factors. Endothelial dysfunction and a reduced generation or bioavailability of NO have emerged as major pathophysiological mechanisms in ED. Hyperlipidemia may impair erectile function by affecting endothelial and smooth muscle cells of the penis. Oxidized low-density lipoprotein is a causative factor for the impaired relaxation response of the corpus cavernosum. Elevated serum cholesterol and reduced high density lipoprotein cholesterol levels are associated with an increased risk of ED. It follows that treating dyslipidemia could have a beneficial effect on ED. Phosphodiesterase type 5 inhibitors are now considered as first line treatment for ED. There is evidence that statins improve responses to these drugs. ED is considered as a warning sign of silent or early vascular disease. The use of statins may be beneficial in these patients.

show abstract

Section: Lipids and The Treatment Of Edmentioning

confidence: 99%

Dyslipidemia as a Risk Factor for Erectile Dysfunction

Vrentzos¹,

Paraskevas²,

Mikhailidis

2007

CMC

View full text Add to dashboard Cite

show abstract

“…DM is a leading cause of ED, affecting ≥50% of men with DM worldwide [2]. The prevalence of ED in diabetics is three times higher than in men without DM [3,4]. …”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Effect of Different Doses of Low Energy Shock Wave Therapy on the Erectile Function of Streptozotocin (STZ)-Induced Diabetic Rats

Liu

Zhou

et al. 2013

IJMS

View full text Add to dashboard Cite

To investigate the therapeutic effect of different doses of low energy shock wave therapy (LESWT) on the erectile dysfunction (ED) in streptozotocin (STZ) induced diabetic rats. SD rats (n = 75) were randomly divided into 5 groups (normal control, diabetic control, 3 different dose LESWT treated diabetic groups). Diabetic rats were induced by intra-peritoneal injection of STZ (60 mg/kg) and rats with fasting blood glucose ≥ 300 mg/dL were selected as diabetic models. Twelve weeks later, different doses of LESWT (100, 200 and 300 shocks each time) treatment on penises were used to treat ED (7.33 MPa, 2 shocks/s) three times a week for two weeks. The erectile function was evaluated by intracavernous pressure (ICP) after 1 week washout period. Then the penises were harvested for histological study. The results showed LESWT could significantly improve the erectile function of diabetic rats, increase smooth muscle and endothelial contents, up-regulate the expression of α-SMA, vWF, nNOS and VEGF, and down- regulate the expression of RAGE in corpus cavernosum. The therapeutic effect might relate to treatment dose positively, and the maximal therapeutic effect was noted in the LESWT300 group. Consequently, 300 shocks each time might be the ideal LESWT dose for diabetic ED treatment.

show abstract

“…rectile dysfunction (ED) and its treatment have received widespread attention in both the scientific literature [1][2][3][4][5] and popular press [6][7][8][9][10] over recent years. In many respects, the stimulus for scientific and popular interest in this area has been the development of the phosphodi-E esterase type 5 (PDE5) inhibitors [11][12][13][14][15], which provide effective treatment for this prevalent [16][17][18][19][20] and distressing [21] condition.…”

Section: Introductionmentioning

confidence: 99%

Sexual Experience of Female Partners of Men with Erectile Dysfunction: The Female Experience of Men’s Attitudes to Life Events and Sexuality (FEMALES) Study

Fisher

Rosen

Eardley

et al. 2005

The Journal of Sexual Medicine

296

226

View full text Add to dashboard Cite

Introduction Much research has explored the experience of erectile dysfunction (ED) among men with ED, but far less attention has been paid to the perceptions and sexual experiences of the female partners of men with ED. Aim The objective of this study was to characterize the attitudes, beliefs, and sexual experience of female partners of men with erectile difficulties. Methods Female partners of men with ED who had participated in the Men’s Attitudes to Life Events and Sexuality (MALES) study were recruited for this research via mail or Internet, after their male partners consented to this contact. Female partners of men with ED (N=293) responded to questionnaire measures assessing their frequency of sexual activity and the nature of their sexual experience, both before and after the development of their partner’s ED, and in relation to their partner’s use of phosphodiesterase type 5 (PDE5) inhibitors. Results Women reported engaging in sexual activity significantly less frequently after their partner developed ED in comparison with before (P<0.001). Moreover, significantly fewer women experienced sexual desire, arousal, or orgasm “almost always” or “most times,” and significantly fewer women reported satisfaction with their sexual relationship after their partner developed ED, compared with before (P<0.001). Decreases in female sexual satisfaction and frequency of orgasm were significantly related to the male partner’s self–reported severity of ED (P<0.01). The proportion of women who experienced sexual desire, arousal, and orgasm “almost always” or “most times” was significantly higher in the group whose partners were currently using a PDE5 inhibitor (P<0.05). Conclusion Erectile dysfunction has significant adverse effects on the female partner’s sexual experience. Women with partners who were currently using PDE5 inhibitors had a more satisfying sexual experience than those whose partners did not use a PDE5 inhibitor.

show abstract

Erectile Dysfunction: Anatomical Parameters, Etiology, Diagnosis, and Therapy

Cited by 43 publications

References 56 publications

Dyslipidemia as a Risk Factor for Erectile Dysfunction

Dyslipidemia as a Risk Factor for Erectile Dysfunction

Evaluation of the Effect of Different Doses of Low Energy Shock Wave Therapy on the Erectile Function of Streptozotocin (STZ)-Induced Diabetic Rats

Sexual Experience of Female Partners of Men with Erectile Dysfunction: The Female Experience of Men’s Attitudes to Life Events and Sexuality (FEMALES) Study

Contact Info

Product

Resources

About